Syfovre — pegcetacoplan
Named-patient access overview. Syfovre is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Syfovre
Syfovre (pegcetacoplan) is manufactured by Apellis and indicated for Geographic atrophy secondary to AMD. It is a C3 inhibitor approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Syfovre
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Syfovre for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Syfovre is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Syfovre in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Syfovre in EgyptNamed-patient access, timeline, and regulatory notes
Syfovre in JordanNamed-patient access, timeline, and regulatory notes
Syfovre in KuwaitNamed-patient access, timeline, and regulatory notes
Syfovre in NepalNamed-patient access, timeline, and regulatory notes
Syfovre in Saudi ArabiaNamed-patient access, timeline, and regulatory notes
Syfovre in United Arab EmiratesNamed-patient access, timeline, and regulatory notes
Start a request for Syfovre
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.